Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 6;10(4):e0123201.
doi: 10.1371/journal.pone.0123201. eCollection 2015.

Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study

Elise M J van der Logt  1 , Deborah A J Kuperus  2 , Jan W van Setten  2 , Marius C van den Heuvel  2 , James E Boers  3 , Ed Schuuring  4 , Robby E Kibbelaar  2
Affiliations

Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study

Elise M J van der Logt et al. PLoS One. .

Abstract

HER2 assessment is routinely used to select patients with invasive breast cancer that might benefit from HER2-targeted therapy. The aim of this study was to validate a fully automated in situ hybridization (ISH) procedure that combines the automated Leica HER2 fluorescent ISH system for Bond with supervised automated analysis with the Visia imaging D-Sight digital imaging platform. HER2 assessment was performed on 328 formalin-fixed/paraffin-embedded invasive breast cancer tumors on tissue microarrays (TMA) and 100 (50 selected IHC 2+ and 50 random IHC scores) full-sized slides of resections/biopsies obtained for diagnostic purposes previously. For digital analysis slides were pre-screened at 20x and 100x magnification for all fluorescent signals and supervised-automated scoring was performed on at least two pictures (in total at least 20 nuclei were counted) with the D-Sight HER2 FISH analysis module by two observers independently. Results were compared to data obtained previously with the manual Abbott FISH test. The overall agreement with Abbott FISH data among TMA samples and 50 selected IHC 2+ cases was 98.8% (κ = 0.94) and 93.8% (κ = 0.88), respectively. The results of 50 additionally tested unselected IHC cases were concordant with previously obtained IHC and/or FISH data. The combination of the Leica FISH system with the D-Sight digital imaging platform is a feasible method for HER2 assessment in routine clinical practice for patients with invasive breast cancer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The corresponding author has read the journal's policy and the authors of this manuscript have the following competing interests: EMJvdL: meeting travel expenses reimbursed (Menarini Benelux); ES: speaker’s fee and meeting travel expenses reimbursed (Ventana/Roche, Abbott/Vysis); JEB: meeting travel expenses reimbursed (Ventana/Roche). The Leica HER2 FISH reagents were kindly provided by Menarini Benelux for this study. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. The design of the D-Sight HER2 FISH analysis module (software version 2012 2.1.2).
“Pictures”: at least 4 areas of interest are selected for analysis and pictures are taken automatically. Captured images from different focus planes are combined generating a picture with all signals clearly detectable after removal of unspecific background. “Objectives and tools”: automated nucleus selection and spot counting of the red (HER2) and the green (chromosoom 17 = CEP17) signal is evaluated and corrected by the observer if needed. “Analysis”: supervised-automated scoring is performed on at least two pictures and the ratio between HER2 and CEP17 was generated.
Fig 2
Fig 2. The appearance of Leica FISH HER2 staining.
Representative pictures of HER2 non-amplified invasive breast cancer specimens are shown in A) with a HER2 (red signals) to chromosoom 17 (= CEP17; green signals) ratio <2 and C) with supervised-automated nuclei and spot detection. Examples of HER2 amplified invasive breast cancer specimens are depicted in B) with a HER2/CEP17 ratio >2 and D) with supervised-automated nucleus and spot detection. DAPI counterstaining and original magnification with 100x objective.
See this image and copyright information in PMC

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2012; 49:1374–1403. - PubMed
    1. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987;84:7159–7163. - PMC - PubMed
    1. Baasner S, von Melchner H, Klenner T, Hilgard P, Beckers T. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene 1996;13:901–911. - PubMed
    1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63–69. - PubMed
    1. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK et al. HER-2 testing in breast cancer using parallel tissue-based methods. Jama 2004;291:1972–1977. - PubMed

MeSH terms